E-DRUG: Cost of R&D for new medicines (2)
[in response to Bonnie's question at the end, the problem is lack of
transparency in the finances of pharmaceutical companies. Moderator]
Thanks to Donald Light for this information on the cost of R&D. I think it is
interesting to learn that indeed the cost of R&D is likely to be more
subjective, close to an art, than a firm science. It therefore would follow, in
my opinion, that any debate about R&D and how one can recover investments, also
becomes a difficult one, particularly if one has no means to go into the
details of each research event to establish the costs that applied therein.
This is important, in my view, as the result thereof (the cost of a patent
product) has a direct bearing on how affordable such a product will be, and
therefore on public health.
Are these R&D costs declared any where, open to public view, etc? Is there a
legal / ethical requirement to publish these R&D costs? I think it would be
helpful to know if such information is available to the public, so that this
debate can be better informed.
Bonface Fundafunda PhD., MBA., B.Pharm
Manager, Drug Supply Budget Line
Ministry of Health,
P.O. Box 30205,
Tel: +260 211 25 41 83
Fax: +260 211 25 33 44
Mobile: + 260 979 25 29 00